TITLE

Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program

AUTHOR(S)
Demarteau, Nadia; Breuer, Thomas; Standaert, Baudouin
PUB. DATE
April 2012
SOURCE
PharmacoEconomics;2012, Vol. 30 Issue 4, p337
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Screening and vaccination against human papillomavirus (HPV) can protect against cervical cancer. Neither alone can provide 100% protection. Consequently it raises the important question about the most efficient combination of screening at specified time intervals and vaccination to prevent cervical cancer. Objective: Our objective was to identify the mix of cervical cancer prevention strategies (screening and/or vaccination against HPV) that achieves maximum reduction in cancer cases within a fixed budget. Methods: We assessed the optimal mix of strategies for the prevention of cervical cancer using an optimization program. The evaluation used two models. One was a Markov cohort model used as the evaluation model to estimate the costs and outcomes of 52 different prevention strategies. The other was an optimization model in which the results of each prevention strategy of the previous model were entered as input data. The latter model determined the combination of the different prevention options to minimize cervical cancer under budget, screening coverage and vaccination coverage constraints. We applied the model in two countries with different healthcare organizations, epidemiology, screening practices, resource settings and treatment costs: the UK and Brazil. 100 000 women aged 12 years and above across the whole population over a 1-year period at steady state were included. The intervention was papanicolaou (Pap) smear screening programmes and/or vaccination against HPV with the bivalent HPV 16/18 vaccine (Cervarix [Cervarix is a registered trademark of the GlaxoSmithKline group of companies]). The main outcome measures were optimal distribution of the population between different interventions (screening, vaccination, screening plus vaccination and no screening or vaccination) with the resulting number of cervical cancer and associated costs. Results: In the base-case analysis (= same budget as today), the optimal prevention strategy would be, after introducing vaccination with a coverage rate of 80% in girls aged 12 years and retaining screening coverage at pre-vaccination levels (65% in the UK, 50% in Brazil), to increase the screening interval to 6 years (from 3) in the UK and to 5 years (from 3) in Brazil. This would result in a reduction of cervical cancer by 41% in the UK and by 54% in Brazil from pre-vaccination levels with no budget increase. Sensitivity analysis shows that vaccination alone at 80% coverage with no screening would achieve a cervical cancer reduction rate of 20% in the UK and 43% in Brazil compared with the pre-vaccination situation with a budget reduction of 30% and 14%, respectively. In both countries, the sharp reduction in cervical cancer is seen when the vaccine coverage rate exceeds the maximum screening coverage rate, or when screening coverage rate exceeds the maximum vaccine coverage rate, while maintaining the budget. As with any model, there are limitations to the value of predictions depending upon the assumptions made in each model. Conclusions: Spending the same budget that was used for screening and treatment of cervical cancer in the pre-vaccination era, results of the optimization program show that it would be possible to substantially reduce the number of cases by implementing an optimal combination of HPV vaccination (80% coverage) and screening at pre-vaccination coverage (65% UK, 50% Brazil) while extending the screening interval to every 6 years in the UK and 5 years in Brazil.
ACCESSION #
75899733

 

Related Articles

  • HPV and Cervical Cancer. Leaver, Dennis; Labonte, Geri // Radiation Therapist;Spring2010, Vol. 19 Issue 1, p27 

    Human papillomaviruses (HPVs) are estimated to cause a half million cases of cervical cancer worldwide each year. This article reviews the connection between HPVs and cervical cancer, discusses the HPV vaccine and provides an overview of cervical cancer symptoms, staging and treatment. Case...

  • What If Preventing Cancer Is as Easy as Being Vaccinated? Biedrzycki, Barbara A. // ONS News;Aug2006, Vol. 21 Issue 8, p9 

    The article reports on the development of a human papillomavirus (HPV) vaccine intended for the prevention of cervical cancer among men and women worldwide. HPV has been sought to be the most common sexually transmitted disease with 20 million men and women have been infected. With the approval...

  • Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Stanley, M. // British Journal of Cancer;5/7/2007, Vol. 96 Issue 9, p1320 

    Virtually all cases of cervical cancer and its precursor intra-epithelial lesions are a result of infection with one or other of a subset of genital human papillomaviruses (HPVs), suggesting that prevention of HPV infection by prophylactic vaccination would be a highly effective anticancer...

  • Broad-acting HPV vaccines explored to fight cancer. Dorans, Kirsten // Nature Medicine;Apr2009, Vol. 15 Issue 4, p351 

    The article focuses on targeting L2 protein found within the human papillovirus (HPV) for possible development of vaccines that can fight HVP strains that causes cancer. It cites that current marketed HPV vaccines that target protein known as L1 can only neutralize 70% of cervical cancer. Thus,...

  • Cervical cancer on its way out. Houlton, Sarah // European Pharmaceutical Executive;Sep2006, p12 

    The article reports that cervical cancer can be cured through vaccines Gardasil from Merck & Co. Inc. and Cervarix from GlaxoSmithKline. Cervical cancer is considered as the second most common form of women diseases and the biggest cancer killer caused by human papilloma virus. Both vaccines...

  • Gardasil Again Denied Approval for Women 27-45.  // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, piv 

    The article reports on the approval for the use of Merck & Co. Inc.'s Gardasil cervical cancer vaccine by women aged 27-45. It is stated that Gardasil's efficacy drops once females have been exposed to human papilloma virus (HPV). However, analyst Tim Anderson mentions that Merck could have...

  • CERVARIX.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA10 

    The article offers information on Cervarix vaccine from GlaxoSmithKline. Cervarix has an active ingredient of bivalent human papillomavirus (HPV) vaccine types 16 and 18 vaccine. The drug is used to prevent cervical cancer and cervical intraepithelial neoplasia (CIN) grade 1 in females 10-25...

  • Quadrivalent HPV vaccine prevented cervical neoplasia caused by HPV-16 and HPV-18.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p49 

    The article discusses the effectiveness of quadrivalent vaccines against human papillomavirus (HPV) in healthy young women. It is stated that a quadrivalent vaccine against HPV types 6, 11, 16, and 18 was effective in preventing cervical neoplasia caused by HPV-16 or HPV-18 in healthy young...

  • HPV jab is beneficial even after Ca treatment.  // Pulse;4/4/2012, Vol. 72 Issue 12, p9 

    The article focuses on the benefits of human papilloma virus (HPV) vaccination among women even after cervical cancer treatment, according to a research led by doctor Elmar Joura.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics